Opthea Corp (OPT): Net earnings per share growth forecast for next year

Public company logo of Opthea Ltd. (OPT)

Opthea Limited expects the completion of final sozinibercept tests for the treatment of macular degeneration, which could lead to FDA approval. Patent protection for this unique therapy will ensure high market value for the company's products. The projected change in earnings per share for the coming year visualizes these expectations, where 92.90 represents the current level of the metric. The strategy is anchored by strong medical leadership that enjoys the trust of institutional investors.

OPT - Opthea Ltd Projected earnings per share increase next year over the range 07/04/2022 - 06/28/2025

Metric breakdowns and analytics for opthea.com (OPT)

- price and consensus price forecast:
Price Chart Opthea Ltd.|OPT - Average Forecast Price
- stock exchange capitalization data:
Market Value Opthea|OPT - Full Business Value
- company book value details:
Accounting Value per Share Opthea|OPT - Total Net Assets|Market Capitalization to Book Value Ratio opthea.com|OPT - Aggregate Asset Value
- business debt structure and liquidity details:
Total Debt to Capital Opthea Limited|OPT - Long-Term Liabilities to Capital|Short-Term Debt to Capital Opthea|OPT - Company Aggregate Debts|Debt to Book Value Opthea|OPT - Company Long-Term Loans and Borrowings|Company Short-Term Debt Opthea|Quick Ratio opthea.com
- earnings and market ratios statistics:
OPT - Net Financial Result|Expected Profit Opthea Limited|OPT - Price to Earnings Ratio|Forward P/E Multiple Opthea Limited|OPT - Growth-Adjusted Market Cap to Net Income|Enterprise Value to EBITDA Ratio Opthea|OPT - Company profit before taxes, interest and amortization|Net earnings per share (EPS TTM) Opthea|OPT - Net earnings per one share for the last twelve months|Quarterly EPS earnings growth opthea.com|OPT - Earnings per share growth this year|Net earnings per share growth forecast for next year Opthea Limited
Basic company analysis:Opthea Ltd.
Finished products of opthea.com

For the biopharmaceutical company Opthea Limited (OPT), which is developing the unique VEGF-C/D inhibitor sozinibercept, this indicator reflects the consensus forecast for changes in earnings per share, determining the market value of future successes in AMD therapy. By analyzing the expected annual EPS growth rate for the coming year, an investor assesses the speed of analyst revision, which allows for the timely identification of asset overbought conditions or a fundamental trend reversal.

Competitor analysis for Opthea Limited

Net earnings per share growth forecast for next year Alcon Vision|Expected net earnings per share growth next year Bausch Health BLCO|Net earnings per share growth forecast for next year Glaukos Corporation (GKOS)|APLS: Net earnings per share change forecast for next year|Belite Bio Inc - Expected earnings per share growth for next year|Projected earnings per share increase next year OCUL (Ocular Therapeutix Inc)|Harrow Health - Earnings growth forecast for next year|Expected earnings per share trend next year VRDN (Viridian Corp)|LENZ: Earnings growth forecast for next year|Expected net earnings per share growth next year Oculis (OCS)|EYPT (EyePoint Pharmaceuticals, Inc.) - Earnings growth forecast for next year|Earnings growth forecast for next year Kodiak Sciences Inc|Expected earnings per share growth for next year ALDX (Aldeyra Therapeutics)|KALA (kalarx.com) - Expected earnings per share trend next year|Net earnings per share growth forecast for next year Opus Genetics IRD|OKYO Pharma Ltd - Net earnings per share growth forecast for next year|Adverum - Earnings growth forecast for next year|Consensus forecast of earnings per share growth for next year Outlook Therapeutics Inc OTLK|Clearside (CLSD) - Net earnings per share growth forecast for next year|Expected earnings per share growth for next year NovaBay Pharmaceuticals, Inc.|KPRX (Kiora Pharmaceuticals Inc.) - Earnings growth forecast for next year|Alimera (ALIM) - Consensus forecast of earnings per share growth for next year|Expected earnings per share growth for next year EYEN (Eyenovia, Inc.)|Projected earnings per share increase next year GHSI|Earnings growth forecast for next year OCUP (Ocuphire)